Membrane-disordering effects of β-amyloid peptides
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
β-Amyloid (Aβ) protein is the major constituent of senile plaques and cerebrovascular deposits characteristic of Alzheimer's disease (AD). The causal relationship between Aβ and AD-specific lesions like neurodegeneration and atrophy is still not known. The present article summarizes our studies indicating that rather low concentrations of Aβ significantly alter the fluidity of cell membranes and subcellular fractions from different tissues and different species including humans, as a possible initial step of its biological effects. Using different fluorescent probes our data show clearly that Aβ peptides specifically disturb the acylchain layer of cell membranes in a very distinct fashion. By contrast, membrane properties at the level of the polar heads of the phospholipid bilayer at the interface with membrane proteins are much less affected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“The effect of Ap on membrane fluidity increases with peptide length, is most pronounced for APi.43 and can be detected at concentrations as low as 100 nM. Although this concentration is still above the physiological Ap level in human brain (Pirttila et al, 1996), it is substantially lower than the in vitro concentrati…”
BackgroundLow cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Pike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699
Keller, J. N., Pang, Z., Geddes, J. W., Begley, J. G., Germeyer, A., Waeg, G., & Mattson, M. P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010273.x · Cited by 439
The Presenilins in Alzheimer's Disease--Proteolysis Holds the Key
Haass, C., & Strooper, B. D. (1999) · Science · doi:10.1126/science.286.5441.916 · Cited by 388 · cited 1×
“These properties possibly contribute to genetically determined forms of AD that are associate with relatively high APi.42 brain levels and early development of AD symptoms ( Haass and De Strooper, 1999; Sinha and Lieberburg, 1999).”
BackgroundMitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology
Nagy, Z., Esiri, M. M., LeGris, M., & Matthews, P. M. (1999) · Acta Neuropathologica · doi:10.1007/s004010050997 · Cited by 85
Cited by
Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G., & Du Yan, S. (2005) · The FASEB Journal · doi:10.1096/fj.05-3735fje · Cited by 738
Hauptmann, S., Scherping, I., Dröse, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., & Müller, W. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.005 · Cited by 469
Self-citationTethered Lipid Bilayers on Ultraflat Gold Surfaces
Naumann, R., Schiller, S. M., Giess, F., Grohe, B., Hartman, K. B., Kärcher, I., Köper, I., Lübben, J., Vasilev, K., & Knoll, W. (2003) · Langmuir · doi:10.1021/la0342060 · Cited by 271
Bharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L., Fraser, P., & Verdile, G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161192 · Cited by 202
Curtain, C. C., Ali, F. E., Smith, D. G., Bush, A. I., Masters, C. L., & Barnham, K. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205455200 · Cited by 200
Arispe, N., & Doh, M. (2002) · The FASEB Journal · doi:10.1096/fj.02-0829com · Cited by 189
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Statin effects on cholesterol micro-domains in brain plasma membranes
Kirsch, C., Eckert, G. P., & Mueller, W. E. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01654-4 · Cited by 167
Self-citationMechanism of Neuronal versus Endothelial Cell Uptake of Alzheimer's Disease Amyloid β Protein
Kandimalla, K. K., Scott, O. G., Fulzele, S., Davidson, M. W., & Poduslo, J. F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004627 · Cited by 88
Metadata
- Authors
- Müller, W. E., Kirsch, C., & Eckert, G. P.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2001-08-01
- Volume
- 29
- Issue
- 4
- Pages
- 617-623
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2074444989
- Cited by
- 69
- References
- 6
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.